Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - mupirocin lupin is indicated for the topical treatment of mild impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: white soft paraffin; hexylene glycol; white beeswax; purified water; propylene glycol monostearate; phosphoric acid - indicated for short-term (up to four continuous weeks) relief of inflammatory & pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis & atopic dermatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow - sical is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. sical a is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. sical is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluorouracil, quantity: 5 % w/w - cream - excipient ingredients: methyl hydroxybenzoate; polysorbate 60; purified water; propylene glycol; propyl hydroxybenzoate; stearyl alcohol; white soft paraffin - solar and senile keratoses, bowen's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - levothyroxine sodium, quantity: 25 microgram - tablet - excipient ingredients: purified talc; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch - eltroxin is indicated for the management of demonstrated thyroid hormone deficiency.,eltroxin is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

United States - English - NLM (National Library of Medicine)

ventura corporation ltd - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - octinoxate 0.066 g in 1 g - - helps prevent sunburn.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - ointment - excipient ingredients: white soft paraffin - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - triamcinolone acetonide, quantity: 0.2 mg/g - cream - excipient ingredients: emulsifying wax; lactic acid; purified water; isopropyl palmitate; glycerol; benzyl alcohol; sorbitol solution (70 per cent) (non-crystallising) - indications as at 22 october 1998: in the treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, exzematised psoriasis, neurodermatitis.